Making Emergency Use of Experimental Vaccines Safer

Bibliographic Data

ID15745390
AuthorsArchana Asundi (0000-0003-3910-909X, National Postdoctoral Association, corresponding author), Nahid Bhadelia (0000-0003-4512-2741, University of Massachusetts Chan Medical School)
Year2020
Volume22
Issue1
PagesE43-49
Publication date2020-01-01
Open AccessYes
TypeARTICLE
VenueThe AMA Journal of Ethic (JOURNAL)
Journal identifiersISSN: 2376-6980 • E-ISSN: 2376-6980
PublisherAmerican Medical Association (PUBLISHER • US)
DOI10.1001/amajethics.2020.43
PMID31958390
OpenAlexW2996841353
LanguageEN
Citations received1
References cited7

Ethical and logistical challenges of deploying experimental vaccines in humanitarian emergencies are exacerbated by a paucity of safety and efficacy data. For outbreaks caused by pathogens with high mortality rates and few treatments, such as Ebola virus disease, not offering access to experimental vaccines with some evidence of efficacy can also be ethically suspect. This article recommends (1) gathering more preclinical data about experimental vaccines' safety and (2) improving research infrastructure to enable participation of a wide range of subjects in affected communities over long trial periods. Motivating these goals would facilitate clearer definitions of population vulnerability and risk acceptability

Computer security · Emergency response · Medical emergency · Outbreak · Risk analysis (engineering · SAFER · Computer Science · Medicine · SARS-CoV-2 and COVID-19 Research · Viral gastroenteritis research and epidemiology · Viral Infections and Outbreaks Research · Virology

Tools

Open DOISci-HubOpen Access